Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Development Officer | September 01, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 01, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,313 |
Last balance in matching sequence
After 2026-09-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-01 · Grant · Acquired 164 · Balance 4,149 F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-09-01 · Grant · Acquired 164 · Balance 4,313 F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 4, 2026 01:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-382475 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,313 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 164 | $113.38 | $18,594.32 |
DisclosureSEC source: 0001193125-26-382475 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,149 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 16,300 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-346942 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 16,300 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,770 | $114.04 | $543,956.97 |
DisclosureSEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,985 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,530 | $113.18 | $1,304,933.12 |
DisclosureSEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,755 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 16,300 | $21.65 | $352,895.00 |
DisclosureSEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 3,700 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-338637 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 3,700 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,700 | $113.12 | $418,561.76 |
DisclosureSEC source: 0001193125-26-338637 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,985 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,700 | $21.65 | $80,105.00 |
DisclosureSEC source: 0001193125-26-338637 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-298865 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 952 | $93.54 | $89,048.46 |
DisclosureSEC source: 0001193125-26-298865 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,985 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $93.52 to $93.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 19,048 | $93.11 | $1,773,481.18 |
DisclosureSEC source: 0001193125-26-298865 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,937 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $92.50 to $93.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-298865 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-257618 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $70.60 | $1,412,000.00 |
DisclosureSEC source: 0001193125-26-257618 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,985 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.44 to $70.86 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-257618 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 877 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256015 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,985 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 877 | $70.44 | $61,775.88 |
DisclosureSEC source: 0001193125-26-256015 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,108 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-212118 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $51.83 | $1,036,600.00 |
DisclosureSEC source: 0001193125-26-212118 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $51.60 to $52.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-212118 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $40.97 | $819,400.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.85 to $41.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 23:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-148497 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 11,767 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 11,767 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,767 | $36.01 | $423,729.67 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,767 | $21.65 | $254,755.55 |
DisclosureSEC source: 0001193125-26-122136 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 8,233 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,767 Underlying: Common Stock · 8,233 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,233 | $35.99 | $296,346.01 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,231 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,233 | $21.65 | $178,244.45 |
DisclosureSEC source: 0001193125-26-096653 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 498 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092157 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,231 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 498 | $35.97 | $17,913.06 |
DisclosureSEC source: 0001193125-26-092157 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,733 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089009 · ownership.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-039717 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $40.87 | $817,334.00 |
DisclosureSEC source: 0001193125-26-039717 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,235 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.71 to $41.2804 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-039717 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-26-008023 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $35.18 | $703,656.00 |
DisclosureSEC source: 0001193125-26-008023 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,235 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-26-008023 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · derivative · entry 8 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 640 | $80.88 | $51,760.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 7 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,235 F6 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 19,360 | $80.05 | $1,549,766.06 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 6 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,875 F6 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 5 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 787 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,235 F5 · kind: Transfer of shares without consideration to the Reporting Person. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 787 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Indirect · The Lake Bainwood Living Trust Disclosed balance after: 0 F4 · ownership.nature: Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 224 | $79.78 | $17,870.72 |
DisclosureSEC source: 0001193125-25-307282 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,500 | $80.90 | $364,070.25 |
DisclosureSEC source: 0001193125-25-300821 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 787 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.81 to $81.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 25, 2025 Filed Dec 4, 2025 01:08 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,500 | $80.90 | $364,070.25 |
DisclosureSEC source: 0001193125-25-307194 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Lake Bainwood Living Trust Disclosed balance after: 787 F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.81 to $81.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.direct: On November 26, 2025, the Reporting Person filed a Form 4 that inadvertently reported that the 4,500 shares sold were held directly. By this amendment, the Reporting Person corrects such report by reporting that the shares sold were held indirectly by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee as a result of the transfer that occurred on November 17, 2025, now reported in this amendment. F3 · ownership.nature: Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| November 17, 2025 Filed Dec 4, 2025 01:08 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 5,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307194 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Lake Bainwood Living Trust Disclosed balance after: 5,287 F1 · kind: This transaction was inadvertently omitted from previous filings. F2 · kind: Transfer of shares without consideration to The Lake Bainwood Living Trust. F3 · ownership.nature: Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.